Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06448247
Status:
RECRUITING
Last Update Posted:
2024-06-10
First Post:
2024-06-03
Brief Title:
A Study of SPY001-001 in Healthy Volunteers
Sponsor:
Spyre Therapeutics Inc
Organization:
Spyre Therapeutics Inc
Study Overview
Official Title:
A Phase 1 Randomized Double-Blind Placebo-Controlled Single and Multiple Ascending Dose Study of the Safety Tolerability and Pharmacokinetics of SPY001-001 in Healthy Participants
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 1 randomized double-blind placebo-controlled single- and multiple-dose first in human safety tolerability and pharmacokinetic study of SPY001-001 in healthy participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None